State of Wisconsin Investment Board cut its holdings in Illumina, Inc. (NASDAQ:ILMN) by 3.0% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 179,382 shares of the life sciences company’s stock after selling 5,560 shares during the quarter. State of Wisconsin Investment Board owned about 0.12% of Illumina worth $55,732,000 as of its most recent SEC filing.
A number of other institutional investors have also modified their holdings of the business. Charter Trust Co. grew its stake in Illumina by 28.4% during the 1st quarter. Charter Trust Co. now owns 4,177 shares of the life sciences company’s stock valued at $1,298,000 after acquiring an additional 923 shares in the last quarter. Principal Financial Group Inc. grew its stake in Illumina by 58.3% during the 1st quarter. Principal Financial Group Inc. now owns 343,068 shares of the life sciences company’s stock valued at $106,588,000 after acquiring an additional 126,408 shares in the last quarter. William Blair Investment Management LLC grew its stake in Illumina by 44.0% during the 1st quarter. William Blair Investment Management LLC now owns 67,134 shares of the life sciences company’s stock valued at $20,858,000 after acquiring an additional 20,510 shares in the last quarter. Jennison Associates LLC grew its stake in Illumina by 3.7% during the 1st quarter. Jennison Associates LLC now owns 5,679,678 shares of the life sciences company’s stock valued at $1,764,619,000 after acquiring an additional 200,114 shares in the last quarter. Finally, AlphaCrest Capital Management LLC grew its stake in Illumina by 75.5% during the 1st quarter. AlphaCrest Capital Management LLC now owns 1,755 shares of the life sciences company’s stock valued at $545,000 after acquiring an additional 755 shares in the last quarter. Hedge funds and other institutional investors own 89.69% of the company’s stock.
Shares of ILMN stock opened at $368.15 on Friday. Illumina, Inc. has a 12 month low of $268.62 and a 12 month high of $372.61. The firm has a market capitalization of $52.41 billion, a price-to-earnings ratio of 64.36, a PEG ratio of 2.48 and a beta of 1.07. The stock’s 50 day simple moving average is $327.38. The company has a current ratio of 3.66, a quick ratio of 3.33 and a debt-to-equity ratio of 0.27.
Several equities research analysts recently commented on the company. BidaskClub raised Illumina from a “hold” rating to a “buy” rating in a research note on Tuesday, June 11th. Canaccord Genuity reissued a “buy” rating and issued a $360.00 price target (up previously from $350.00) on shares of Illumina in a research note on Monday, June 10th. Wolfe Research assumed coverage on Illumina in a research note on Thursday, May 30th. They issued an “outperform” rating for the company. OTR Global cut Illumina to a “positive” rating in a research note on Tuesday, April 2nd. Finally, Zacks Investment Research lowered Illumina from a “buy” rating to a “hold” rating in a report on Wednesday, March 27th. Two equities research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $354.35.
In other news, insider Francis A. Desouza sold 3,000 shares of the company’s stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $315.93, for a total transaction of $947,790.00. Following the completion of the transaction, the insider now directly owns 75,646 shares in the company, valued at $23,898,840.78. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Jay T. Flatley sold 3,300 shares of the company’s stock in a transaction that occurred on Wednesday, June 26th. The stock was sold at an average price of $358.15, for a total value of $1,181,895.00. Following the transaction, the director now owns 275,916 shares of the company’s stock, valued at $98,819,315.40. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 60,291 shares of company stock valued at $19,409,459. Corporate insiders own 0.38% of the company’s stock.
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.
Featured Article: What is the price-to-earnings growth (PEG) ratio?
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.